Latest Regulatory Filings News

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

Vinyl Group Ltd has had its trading suspension lifted following a Federal Court decision related to its previous non-compliance with cleansing notice requirements.

Vinyl Group has applied to the Federal Court for an extension to lodge delayed cleansing notices, aiming to lift its ASX trading suspension. The court hearing is set for 5 June 2025, with market watchers awaiting the outcome.

Neuren Pharmaceuticals has approved a significant long-term equity incentive plan tied to critical clinical and regulatory milestones for its drug candidate NNZ-2591, reinforcing management’s commitment to shareholder value.

Alice Queen Limited is set to raise nearly $1 million through a two-tranche share placement, with substantial shareholder support and options attached, aiming to fuel exploration at its Viani project.

Mount Burgess Mining NL has voluntarily suspended trading of its shares on the ASX pending a court ruling on the validity of a recent cleansing notice tied to new share issuance.

Donaco International Limited has postponed its Scheme of Arrangement timetable amid extended legal and valuation reviews, while revealing a new 10% VAT gaming tax liability in Cambodia effective from January 2025.

DMC Mining Limited has extended the closing date for its public share offer to August 2025 due to delays in securing exploration licences for its key Guinea projects. The company plans further regulatory updates to accommodate these changes.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Bio-Gene Technology Limited has been awarded two significant grants totaling A$3 million by the US Department of Defense, validating its innovative insecticide technologies Flavocide® and Qcide®. The company is advancing regulatory filings and scaling production to target both military and civilian markets.